TY - JOUR
T1 - Outcomes of a randomized controlled trial assessing a smartphone Application to reduce unmet needs among people diagnosed with CancEr (ACE)
AU - Livingston, Patricia M.
AU - Heckel, Leila
AU - Orellana, Liliana
AU - Ashley, David
AU - Ugalde, Anna
AU - Botti, Mari
AU - Pitson, Graham
AU - Woollett, Anne
AU - Chambers, Suzanne K.
AU - Parente, Phillip
AU - Chirgwin, Jacqueline
AU - Mihalopoulos, Cathrine
AU - Lavelle, Barbara
AU - Sutton, Jennifer
AU - Phipps-Nelson, Jo
AU - Krishnasamy, Mei
AU - Simons, Katherine
AU - Heynsbergh, Natalie
AU - Wickramasinghe, Nilmini
AU - White, Vicki
N1 - Funding Information:
We acknowledge the significant support and contribution from Mr Fadi Geha, CEO and staff, Simble Solutions? and Optus? in the development and execution of the smartphone app. We also acknowledge Associate Professor John Reynolds for his statistical contribution in the development stage of the grant, Associate Professor Anna Boltong in the early stages of the study design and implementation of the study, and Eric O who provided advice on the smartphone app usage analysis. We thank health service research staff and ICS personnel, including Jenny Byrne and Sue Riches, who supported this study.
Publisher Copyright:
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2020/1
Y1 - 2020/1
N2 - Background: Smartphone technology represents an opportunity to deliver practical solutions for people affected by cancer at a scale that was previously unimaginable, such as information, appointment monitoring, and improved access to cancer support services. This study aimed to determine whether a smartphone application (app) reduced the unmet needs among people newly diagnosed with cancer. Methods: A single blind, multisite randomized controlled trial to determine the impact of an app-based, 4-month intervention. Newly diagnosed cancer patients were approached at three health service treatment clinics. Results: Eighty-two people were randomized (intervention; n = 43 and control; n = 39), average age was 59.5 years (SD: 12.9); 71% female; 67% married or in a de facto relationship. At baseline, there were no differences in participants’ characteristics between the groups. No significant effects, in reducing unmet needs, were demonstrated at the end of intervention (4-month) or 12-month follow-up. Overall, 94% used the app in weeks 1-4, which decreased to 41% in weeks 13-16. Mean app use time per participant: Cancer Information, 6.9 (SD: 18.9) minutes; Appointment Schedule, 5.1 (SD: 9.6) minutes; Cancer Services 1.5 minutes (SD: 6.8); Hospital Navigation, 1.4 (SD: 2.8) minutes. Conclusions: Despite consumer involvement in the design of this smartphone technology, the app did not reduce unmet needs. This may have been due to the study being underpowered. To contribute to a meaningful understanding and improved implementation of smartphone technology to support people affected by cancer, practical considerations, such as recruitment issues and access to, and confidence with, apps, need to be considered. Australian New Zealand Clinical Trials Registration (ACTRN) Trial Registration: 12616001251415; WEF 7/9/2016.
AB - Background: Smartphone technology represents an opportunity to deliver practical solutions for people affected by cancer at a scale that was previously unimaginable, such as information, appointment monitoring, and improved access to cancer support services. This study aimed to determine whether a smartphone application (app) reduced the unmet needs among people newly diagnosed with cancer. Methods: A single blind, multisite randomized controlled trial to determine the impact of an app-based, 4-month intervention. Newly diagnosed cancer patients were approached at three health service treatment clinics. Results: Eighty-two people were randomized (intervention; n = 43 and control; n = 39), average age was 59.5 years (SD: 12.9); 71% female; 67% married or in a de facto relationship. At baseline, there were no differences in participants’ characteristics between the groups. No significant effects, in reducing unmet needs, were demonstrated at the end of intervention (4-month) or 12-month follow-up. Overall, 94% used the app in weeks 1-4, which decreased to 41% in weeks 13-16. Mean app use time per participant: Cancer Information, 6.9 (SD: 18.9) minutes; Appointment Schedule, 5.1 (SD: 9.6) minutes; Cancer Services 1.5 minutes (SD: 6.8); Hospital Navigation, 1.4 (SD: 2.8) minutes. Conclusions: Despite consumer involvement in the design of this smartphone technology, the app did not reduce unmet needs. This may have been due to the study being underpowered. To contribute to a meaningful understanding and improved implementation of smartphone technology to support people affected by cancer, practical considerations, such as recruitment issues and access to, and confidence with, apps, need to be considered. Australian New Zealand Clinical Trials Registration (ACTRN) Trial Registration: 12616001251415; WEF 7/9/2016.
KW - cancer education
KW - clinical cancer research
KW - smartphone technology
KW - translational research
UR - http://www.scopus.com/inward/record.url?scp=85075462384&partnerID=8YFLogxK
U2 - 10.1002/cam4.2718
DO - 10.1002/cam4.2718
M3 - Article
C2 - 31769226
AN - SCOPUS:85075462384
VL - 9
SP - 507
EP - 516
JO - Cancer Medicine
JF - Cancer Medicine
SN - 2045-7634
IS - 2
ER -